
    
      This is a Phase 2, proof of concept, two-arm, randomized, double blind, placebo-controlled
      study to evaluate the safety and efficacy of Prothione™ capsules in subjects with
      mild-to-moderate symptoms caused by coronavirus 2019 (COVID-19) infection. Subjects will be
      randomized to receive three Prothione™ capsules, or placebo orally administered twice daily
      (BID).

      The study will have three phases: screening period, treatment period, and follow-up period.
      Screening period is up to 3 days , the treatment period is 30 days and the follow-up period
      is 7 days after the last dose.Total study duration is up to 40 days.
    
  